Incidence of Newly Recognized Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten

Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2 However, the effect of mavacamten on the frequency and management of new/recurrent AF episodes in oHCM receiving mavacamten following its Food and Drug Administration (FDA) approval remains only partially explored.

Source: Heart Rhythm - April 13, 2024 Category: Cardiology Authors: Matteo Castrichini, Said Alsidawi, Jeffrey B. Geske, Darrell B. Newman, Adelaide M. Arruda-Olson, J. Martijn Bos, Steve R. Ommen, Konstantinos C. Siontis, Michael J. Ackerman, John R. Giudicessi Source Type: research